Venture Life Group Plc · LSE:VLG
Venture Life — H1 2025 Earnings Presentation
25 slides from Venture Life's earnings presentation, September 2025
Slide 1: Proactive Healthy Longevity
Proactive Healthy Longevity Results update for the 6 months ended 30th June 2025 September 2025
Slide 2: Highlights
Highlights Continuing operations (excl. Oral Care) • Group revenue grew 43.1% to £15.4m (proforma 12.4%) through increased A&P • Gross margin increased by 0.9ppts to 43.1% (2024: 41.2%) • Adjusted EBITDA £1.8m (2024: £1.4m) and Adjusted EBITDA margin 11.6% (2024: 12.6%) • Free cash flow before cash
Slide 3: Financial Headlines
Financial Headlines • Group revenue increased 43.1% to £15.4 million (2024: £10.8 million) and growth of 12.4% on a proforma basis. • Gross profit increased 49.9% to £6.6 million (2024: £4.4 million) and gross margin improvement to 43.1% (2024: 41.2%) (2024 proforma: 43.0%). • Marketing costs as % o
Slide 4: At a Glance – Brands Performance
AT A GLANCE – BRANDS PERFORMANCE CATEGORY % OF GROUP REVENUE IN H1 2025 YOY GROWTH KEY BRANDS Women’s Intimate Health 26.7% +24.2% Hormone Health 26.5% +38.1% Energy Management 25.9% (4.7%) Ear, Nose & Throat 16.3% (10.7)% Oncology Support 4.6% +204.6%
Slide 5: Our Business Model and Strategy
OUR BUSINESS MODEL AND STRATEGY Our strategy • Acquiring and transforming Long-term supply agreement core brands with a clear EXTERNAL runway for profitable growth MANUFACTURING 3rd Party CDMOs CENTRES • A No. 1 brand mindset • Omnichannel go-to-market strategy tailored to where shoppers shop and ho
Slide 6: Become the partner of choice for Proactive Healthy Longevity
Become the partner of choice for: Simplifying will allow us to: Proactive Evolve – pure brand platform Healthy Invest – in power brands Longevity Innovate – with data driven insight Grow – in key markets (US/EU/UK) “healthspan” The ambition: The Partner of choice for Proactive Healthy Longevity
Slide 7: 5 strategic pillars
9 5 strategic pillars Acquiring & transforming core brands with a clear runway for profitable growth Number 1 Brand mindset Omnichannel go to market strategy tailored to where shoppers’ shop & how they buy Integrated digital capabilities with advanced AI & robust data to drive insights Winning Ways
Slide 8: Prevention & treatment products which improve healthspans
Prevention & treatment products which improve healthspans The ambition: The Partner of choice for Proactive Healthy Longevity
Slide 9: Corporate Development
Corporate Development • 2025 - Business structure simplification and entity streamlining • 2025 – New ERP system – will be completed by end of 2025 • July 2025 - Divestment of CDMO operations and some small brands, launch of new focused strategy • Oral care divestment expected during H2 2025 • Reten
Slide 10: M&A Strategy
M&A Strategy • Complementary categories, adjacencies • Margin enhancing • Sensibly priced • Asset purchases preferred • Currently interacting with targets • Watch this space
Slide 11: Hormonal Health
Hormonal Health 12
Slide 12: Hormonal Health 2025 H1 (Revenue +38%)
Hormonal Health 2025 H1 (Revenue +38%) Health & Her and Health & Him +35% +72% Net Revenue vs 1H Distribution Points Active Products New Products 1H25 2024 • US Retail Expansion: +15,000 US distribution points with 3 additional products listed in CVS • UK Retail: Range extensions for new multivitami
Slide 13: Hormonal Health 2025 H2 Plans
Hormonal Health 2025 H2 Plans Health & Her and Health & Him Active Products New Products in 2H +5,486 +11 distribution pts New Products • Innovation into reproductive health: New fertility, pregnancy, new mum and new dad range launching in Q4 • Other innovation: H&Him Prostaguard for prostate suppor
Slide 14: Women's Health
BALANCE ACTIV" Women’s Health
Slide 15: Women's Health H1 (Revenue +13%)
Women’s Health Women’s Health H1 (Revenue +13%) Therapy highlights UK & EU +34% +9% Grocery growth YoY Online growth YoY H1 2025 • Recently launched (latest 2 years) treatment conditions demonstrating good organic growth due to key product extensions in retail and consumer awareness • Grocery +34% Y
Slide 16: Women's Health H2 2025
Women’s Health Women’s Health H2 2025 Therapy highlights UK & EU +332 5 Dist. Points Innovations in Development H2 Plans 2025 • Innovation: A big drive to fill treatment innovation pipeline 26/27 inclusive of breakthrough and first to market innovations. • New Listing in Holland & Barrett thanks to
Slide 17: Slide 17
Slide 18: Energy Management H1 (Revenue -4.7%)
Energy Management H1 (Revenue -4.7%) +30% Online growth +£80k Glucogel launched on Amazon H1 2025 • Online channel is up +30% with Amazon and recently launched lift.com performing well • Glucogel launch on amazon UK is also delivering incremental sales and benefiting from HCP recommendation • Need a
Slide 19: Energy Management H2 Plans
Energy Management H2 Plans 5 Innovations in Development H2 2025 • Developing far-reaching sampling and education campaign to HCPs including training guides and CPD modules • Leveraging new in-house digital team to build out CRM program and drive subscriptions and loyalty on lift.com • Developing inn
Slide 20: Venture Life Group plc
Venture Life Group plc 21
Slide 21: ENT H1 (Revenue -10.7%)
ENT ENT H1 (Revenue -10.7%) Therapy highlights UK & EU “UK’s No.1 ear wax removal spray” +15% UK NR growth YoY +1,400 new distribution points H1 2025 • Earol Distribution Expansion in Sainsburys, Morrisons and WH Smith saw an increase of +1400 distribution points • Grocery placement strategy to more
Slide 22: ENT H2 Plan
ENT ENT H2 Plan Therapy highlights UK & EU Retail +995 Dist Points Growth +1 New Retailer H2 2025 • New Listing in Holland & Barrett from Q4 • Earol received the 2025 Highly Commended Award from MVP Awards reinforcing our credibility and leadership in the ear care category • “Ask the Expert” - consu
Slide 23: VLG: simplified for growth
VLG: simplified for growth • Capital light structure • Brand focus, high margins, no.1 mindset • Data driven insight • Omnichannel • Digitally integrated • Pure play CHC • Entrepreneurial • Core geographic market focus
Slide 24: Outlook
Outlook • Simplified capital light structure • Focused on higher margin higher multiple CHC landscape • Sector historic exit multiples 14.6x EBITDA • Net cash position circa £34m (post-completion of CDMO divestment) • RCF up to £5om available • Clear strategic focus • Investment in organic growth •
Slide 25: Thank You
Thank You The ambition: The Partner of choice for Proactive Healthy Longevity